Related Experiment Video

Updated: May 14, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Tumor necrosis factor inhibitor-induced serositis

Narender Annapureddy1, Shiv Kumar Agarwal, Natraj Ammakkanavar

  • 11Department of Rheumatology, The Orthopedic Building at Rush University Medical Center, Rush University Medical Center, Chicago, IL; 2Department of Medicine, St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY; 3Department of Hematology/Oncology, Indiana University, Indianapolis, IN; 4Department of Gastroenterology, Kansas City VA Medical Center, Kansas City, MO; 5Department of Cardiology, Albert Einstein College of Medicine, Bronx, NY; 6Osmania Medical College, Hyderabad, India; and 7Department of Nephrology, The Mount Sinai School of Medicine, New York, NY.

American Journal of Therapeutics
|January 25, 2013
PubMed

Insights

A patient on adalimumab developed unexplained pleural effusion, a form of serositis. Treatment with corticosteroids led to recovery, suggesting an immune-related adverse effect.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Immunology

Background:

  • Adalimumab is a TNF-alpha inhibitor used for autoimmune conditions like psoriatic arthritis.
  • Pleural effusion can be a rare complication of biologic therapies.
  • Accurate diagnosis is crucial for appropriate management.

Observation:

  • A 46-year-old man with asthma and psoriatic arthritis presented with fever, tachycardia, and hypoxia.
  • He was diagnosed with exudative pleural effusion and initially treated with antibiotics without improvement.
  • Blood and pleural fluid cultures were negative.

Findings:

  • The patient showed remarkable recovery after initiating prednisone treatment.
  • The condition was diagnosed as adalimumab-induced serositis.
  • This highlights a potential immune-related adverse event of adalimumab therapy.

Implications:

  • Adalimumab-induced serositis should be considered in patients on this biologic agent presenting with unexplained pleural effusions.
  • Corticosteroid therapy may be effective in managing this condition.
  • Further research into the mechanisms of biologic-induced serositis is warranted.

More Related Videos

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...